Dataset Information

Global analysis of plasma lipidomics reveals altered lipid signatures in patients with osteonecrosis of the femoral head

ABSTRACT:

AIMS: Although studies have made the connection between lipid metabolism disorder and osteonecrosis of the femoral head (ONFH), the characteristics of the circulating lipidome signature of ONFH have not yet been investigated yet and need to be explored.

METHODS: We conducted a comprehensive analysis of plasma lipidomics in a clinical human cohort including 32 healthy normal control (NC) subjects and 91 ONFH patients in different subgroups (alcohol-induced [AONFH], steroid-induced, and traumatic ONFH) and stages (stages I/II, stages III/IV), using ultra-high performance liquid chromatography–tandem mass spectrometry.

RESULTS: The PLS-DA model indicates that the global plasma lipidome profile differs between the ONFH and NC samples. We identified a signature including 22 common differentially expressed lipids (DELs) in all the three subgroups (VIP > 1, P < 0.05, FC > 1.5 or FC < 0.67, compared with the NC group), and for each of the subtype-specific lipidome profiles, as well as altered lipid biomarkers (FC > 2, P < 0.05, and AUC > 0.7, compared with the NC group) for each subgroup. The AONFH subgroup has the most DELs, and the plasma levels of lipid compounds in the subclass of triacylglycerol increased obviously in the AONFH samples. We identified that 9 stage-positive and 2 stage-negative lipids may function as novel biomarkers that predict the disease progression of ONFH.

CONCLUSION: This study provides the first overview, analysis, and understanding of the unique phenotype-related plasma lipidome signature of ONFH. The results will offer insights into the mechanisms underlying lipid metabolism in the pathogenesis and progression of ONFH, and will help to identify novel lipids biomarkers or targets for disease diagnosis and treatment.

INSTRUMENT(S): Liquid Chromatography MS - negative - reverse phase, Liquid Chromatography MS - positive - reverse phase

SUBMITTER: Jihan Wang

PROVIDER: MTBLS2262 | MetaboLights | 2021-07-06

REPOSITORIES: MetaboLights

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	MTBLS2262	Other
	FILES	Other
	a_MTBLS2262_LC-MS_negative_reverse-phase_metabolite_profiling.txt	Txt
	a_MTBLS2262_LC-MS_positive_reverse-phase_metabolite_profiling-1.txt	Txt
	i_Investigation.txt	Txt

Items per page:

1 - 5 of 8

Similar Datasets

Project description:Recent genomic approaches have suggested the existence of multiple distinct subtypes of medulloblastoma. We studied a large cohort of medulloblastomas to determine how many subgroups of the disease exist, how they differ, and the extent of overlap between subgroups. We determined gene expression profiles and DNA copy number aberrations for 103 primary medulloblastomas. Bioinformatic tools were used for class discovery of medulloblastoma subgroups based on the most informative genes in the dataset. Immunohistochemistry for subgroup-specific ‘signature’ genes was used to determine subgroup affiliation for 294 non-overlapping medulloblastomas on two independent tissue microarrays (TMAs). Multiple unsupervised analyses of transcriptional profiles identified four distinct, non-overlapping molecular variants: WNT, SHH, Group C, and Group D. Supervised analysis of these four subgroups revealed significant subgroup-specific demographics, histology, metastatic status, and DNA copy number aberrations. Immunohistochemistry for DKK1 (WNT), SFRP1 (SHH), NPR3 (Group C), and KCNA1 (Group D) could reliably and uniquely classify formalin fixed medulloblastomas in ~98% of cases. Group C patients (NPR3 +ve tumors) exhibited a significantly diminished progression free and overall survival irrespective of their metastatic status. Our integrative genomics approach to a large cohort of medulloblastomas has identified four disparate subgroups with distinct demographics, clinical presentation, transcriptional profiles, genetic abnormalities, and clinical outcome. Medulloblastomas can be reliably assigned to subgroups through immunohistochemistry, thereby making medulloblastoma sub-classification widely available. Future research on medulloblastoma and the development of clinical trials should take into consideration these four distinct types of medulloblastoma. A total of 103 primary medulloblastoma specimens were profiled by Affymetrix exon array and gene-level analysis was performed.

Dataset Information

Global analysis of plasma lipidomics reveals altered lipid signatures in patients with osteonecrosis of the femoral head

Dataset's files

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets